These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28990424)

  • 1. An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria.
    Serrano-Mendioroz I; Sampedro A; Alegre M; Enríquez de Salamanca R; Berraondo P; Fontanellas A
    Hum Gene Ther; 2018 Apr; 29(4):480-491. PubMed ID: 28990424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice.
    Unzu C; Sampedro A; Mauleón I; González-Aparicio M; Enríquez de Salamanca R; Prieto J; Aragón T; Fontanellas A
    Hum Mol Genet; 2013 Jul; 22(14):2929-40. PubMed ID: 23562909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria.
    Pañeda A; Lopez-Franco E; Kaeppel C; Unzu C; Gil-Royo AG; D'Avola D; Beattie SG; Olagüe C; Ferrero R; Sampedro A; Mauleon I; Hermening S; Salmon F; Benito A; Gavira JJ; Cornet ME; del Mar Municio M; von Kalle C; Petry H; Prieto J; Schmidt M; Fontanellas A; González-Aseguinolaza G
    Hum Gene Ther; 2013 Dec; 24(12):1007-17. PubMed ID: 24070415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
    D'Avola D; López-Franco E; Sangro B; Pañeda A; Grossios N; Gil-Farina I; Benito A; Twisk J; Paz M; Ruiz J; Schmidt M; Petry H; Harper P; de Salamanca RE; Fontanellas A; Prieto J; González-Aseguinolaza G
    J Hepatol; 2016 Oct; 65(4):776-783. PubMed ID: 27212246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function.
    Yasuda M; Bishop DF; Fowkes M; Cheng SH; Gan L; Desnick RJ
    Mol Ther; 2010 Jan; 18(1):17-22. PubMed ID: 19861948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria.
    Johansson A; Nowak G; Möller C; Harper P
    Mol Genet Metab; 2004 May; 82(1):20-6. PubMed ID: 15110317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
    Johansson A; Nowak G; Möller C; Blomberg P; Harper P
    Mol Ther; 2004 Aug; 10(2):337-43. PubMed ID: 15294180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmenting PBGD expression in the liver as a novel gene therapy for acute intermittent porphyria (AIPgene).
    Hum Gene Ther Clin Dev; 2014 Jun; 25(2):61-3. PubMed ID: 24933563
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute intermittent porphyria: vector optimization for gene therapy.
    Yasuda M; Domaradzki ME; Armentano D; Cheng SH; Bishop DF; Desnick RJ
    J Gene Med; 2007 Sep; 9(9):806-11. PubMed ID: 17654633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
    Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
    Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.
    Jiang L; Berraondo P; Jericó D; Guey LT; Sampedro A; Frassetto A; Benenato KE; Burke K; Santamaría E; Alegre M; Pejenaute Á; Kalariya M; Butcher W; Park JS; Zhu X; Sabnis S; Kumarasinghe ES; Salerno T; Kenney M; Lukacs CM; Ávila MA; Martini PGV; Fontanellas A
    Nat Med; 2018 Dec; 24(12):1899-1909. PubMed ID: 30297912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.
    Serrano-Mendioroz I; Sampedro A; Serna N; de Salamanca RE; Sanz-Parra A; Corrales F; Berraondo P; Millet O; Fontanellas A
    Hum Mol Genet; 2018 Nov; 27(21):3688-3696. PubMed ID: 30085095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency.
    Collantes M; Serrano-Mendioroz I; Benito M; Molinet-Dronda F; Delgado M; Vinaixa M; Sampedro A; Enríquez de Salamanca R; Prieto E; Pozo MA; Peñuelas I; Corrales FJ; Barajas M; Fontanellas A
    Hum Mol Genet; 2016 Apr; 25(7):1318-27. PubMed ID: 26908609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
    Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
    Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice.
    Unzu C; Sampedro A; Mauleón I; Alegre M; Beattie SG; de Salamanca RE; Snapper J; Twisk J; Petry H; González-Aseguinolaza G; Artieda J; Rodríguez-Pena MS; Prieto J; Fontanellas A
    Mol Ther; 2011 Feb; 19(2):243-50. PubMed ID: 20877347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
    Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
    Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-viral mediated gene transfer of porphobilinogen deaminase into mammalian cells.
    Johansson A; Möller C; Gellerfors P; Harper P
    Scand J Clin Lab Invest; 2002; 62(2):105-13. PubMed ID: 12004925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery.
    Johansson A; Möller C; Harper P
    Mol Cell Biochem; 2003 Aug; 250(1-2):65-71. PubMed ID: 12962144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
    Lindberg RL; Porcher C; Grandchamp B; Ledermann B; Bürki K; Brandner S; Aguzzi A; Meyer UA
    Nat Genet; 1996 Feb; 12(2):195-9. PubMed ID: 8563760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.